Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of subcutaneous human immunoglobulin in primary immunodeficiency
CTR20253030Phase 3Active
- Sponsor
- China Resources Boya Bio-pharmaceutical Group
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Gamimune-N in Immunogenetic disorder, X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), IgG subclass deficiency (IgGSD), sponsored by China Resources Boya Bio-pharmaceutical Group. Started Aug 2025; status: active.
02
Drugs
Gamimune-N
03
Conditions
Immunogenetic disorderX-linked agammaglobulinemia (XLA)common variable immunodeficiency (CVID)IgG subclass deficiency (IgGSD)
Beyond the preview
Go deeper on CTR20253030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253030.